Oblenio Bio raised $62M in a Series B led by Pfizer Ventures to advance LBL-051 into clinical trials for autoimmune disease.
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.